| 1. An integrated traditional Chinese and Western Medicine study on the comprehensive prevention and treatment of chronic hepatitis B and its related diseases |
Page:1257—1266 |
| 2. Research advances in kidney-tonifying therapy for patients with HBeAg-positive chronic HBV infection |
Page:1267—1273 |
| 3. Clinical efficacy and mechanism of action of kidney-tonifying, spleen-strengthening, and diuresis-promoting therapy in treatment of chronic hepatitis B |
Page:1274—1279 |
| 4. Role of traditional Chinese Medicine in prevention and treatment of chronic hepatitis B liver fibrosis: Current status, challenges, and thoughts |
Page:1280—1286 |
| 5. Chinese expert consensus on management of thrombocytopenia in cancer patients with liver injury (2022 edition) |
Page:1287—1294 |
| 6. Debates on the natural history of chronic hepatitis B virus infection during the update of Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2022 Version) |
Page:1295—1298 |
| 7. Evolution in the indications for anti-viral therapy in chronic hepatitis B |
Page:1299—1303 |
| 8. Liver inflammation and fibrosis in HBV-infected patients with a low viral load |
Page:1304—1307 |
| 9. Value of platelet count and related scoring models in predicting the prognosis of hepatitis B virus-related acute-on-chronic liver failure |
Page:1308—1312 |
| 10. Influence of long-term use of entecavir on renal tubular function in patients with chronic hepatitis B |
Page:1313—1317 |
| 11. Value of |
Page:1318—1324 |
| 12. Value of atherogenic index of plasma in predicting metabolic associated fatty liver disease in patients with type 2 diabetes mellitus |
Page:1325—1331 |
| 13. Clinical features of hypopituitarism with nonalcoholic fatty liver disease after sellar tumor surgery in children |
Page:1332—1339 |
| 14. Effect of Xuanfuhua decoction on a mouse model of nonalcoholic steatohepatitis induced by high-fat, high-fructose, and high-cholesterol diet |
Page:1340—1350 |
| 15. Role and mechanism of action of the Mongolian medicine |
Page:1351—1357 |
| 16. Current reviewers |
Page:1357—1357 |
| 17. Clinical features of patients with drug-induced liver injury in Shaanxi Province from 2009 to 2019 |
Page:1358—1365 |
| 18. Distribution and drug resistance of pathogenic bacteria for infection after liver transplantation |
Page:1366—1373 |
| 19. Influencing factors for dynamic changes in the severity of fatty liver in patients with acute pancreatitis and fatty liver |
Page:1374—1381 |
| 20. Influencing factors for persistent inflammation, immunosuppression, and catabolism syndrome in patients with severe acute pancreatitis and establishment of a predictive model |
Page:1382—1390 |
| 21. Value of five scoring systems in predicting the severity of hyperlipidemic acute pancreatitis: A comparative analysis |
Page:1391—1397 |
| 22. Value of atherogenic index of plasma combined with Bedside Index for Severity in Acute Pancreatitis in the early prediction of severe hypertriglyceridemic acute pancreatitis |
Page:1398—1403 |
| 23. A case of primary biliary cholangitis with connective tissue disease and immune thrombocytopenia |
Page:1404—1407 |
| 24. Congenital left hepatic deficiency with hepatocellular carcinoma: A case report |
Page:1408—1410 |
| 25. Multidisciplinary diagnosis and treatment of primary hepatic neuroendocrine tumor |
Page:1411—1413 |
| 26. Cavernous transformation of the portal vein caused by myeloproliferative disease: A case report |
Page:1414—1417 |
| 27. Association of inhibitory receptor T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain with immune disorders in chronic HBV infection |
Page:1418—1423 |
| 28. Association between immune checkpoint inhibitor antitumor therapy and hepatitis B virus reactivation |
Page:1424—1430 |
| 29. Research advances in cytomegalovirus hepatitis |
Page:1431—1439 |
| 30. Role of intrahepatic microenvironment induced-autophagy in nonalcoholic fatty liver disease |
Page:1440—1445 |
| 31. Research advances in nonalcoholic fatty liver disease in individuals with HIV infection |
Page:1446—1453 |
| 32. Research advances in the cascade interaction between reactive oxygen species/reactive nitrogen species and the NF-κB signaling pathway in liver fibrosis |
Page:1454—1460 |
| 33. Advances in the pathogenesis, diagnosis, and treatment of renal injury in liver cirrhosis |
Page:1461—1467 |
| 34. Research advances in early screening and diagnosis of hepatocellular carcinoma |
Page:1468—1475 |
| 35. Research advances in natural killer cell-based immunotherapy in liver cancer |
Page:1476—1481 |
| 36. Current research status of left-sided portal hypertension after superior mesenteric-portal vein confluence pancreaticoduodenectomy |
Page:1482—1487 |
| 37. Role of purine signaling in liver immune regulation |
Page:1488—1496 |
| 38. Research advances in the pathogenesis, phenotype-genotype relationship, and pharmacotherapy of hepatolenticular degeneration |
Page:1497—1504 |
